Beijing Biostar Technologies Ltd (HKG: 2563) announced that its wholly‑owned U.S. subsidiary, Biostar Pharma, Inc., has completed the first patient dosing in a U.S. pivotal registration clinical trial (NCT06764940) evaluating Utedelone in combination with capecitabine for HER2‑negative Breast Cancer Brain Metastasis (BCBM). Utedelone, a genetically engineered epothilone derivative, was approved in China in March 2021 for recurrent/metastatic breast cancer.
Contents
Regulatory & Clinical Milestone
| Item | Details |
|---|---|
| Study ID | NCT06764940 |
| Trial Type | U.S. pivotal registration clinical trial |
| Population | HER2‑negative breast cancer brain metastasis (BCBM) |
| Regimen | Utedelone + capecitabine |
| First Patient Dosed | December 2025 |
| Prior Approval | March 2021 (China) for recurrent/metastatic breast cancer post‑chemotherapy |
Drug Profile & Competitive Advantages
| Attribute | Utedelone | Competitive Context |
|---|---|---|
| Mechanism | Genetically engineered epothilone derivative | Microtubule stabilizer with broad anticancer spectrum |
| Key Advantages | Broad activity, significant efficacy, favorable safety, lower cost | Differentiated from traditional taxanes |
| Route | Intravenous (IV) infusion | Established administration route |
| Differentiation | Lower cost profile vs. standard BCBM therapies (lapatinib, neratinib) | Addresses affordability in metastatic setting |
| Target Indication | HER2‑negative BCBM (high unmet need) | No approved epothilone specifically for BCBM |
Market Opportunity
| Metric | Value | Context |
|---|---|---|
| BCBM Prevalence | 30‑50% of HER2‑negative metastatic breast cancer patients develop brain metastases | ~20,000‑30,000 eligible patients annually in US/EU |
| HER2‑Negative BCBM Market | $500‑800 million (global, 2025) | Dominated by HER2‑targeted agents (not applicable to HER2‑negative) |
| Utedelone Peak Sales | $200‑350 million (global estimate) | 15‑20% share if approved in BCBM |
| Competitive Landscape | Limited options: radiation, surgery, off‑label chemotherapy | First epothilone in registration trial for BCBM |
Strategic Implications
- For Biostar: First US registration trial for a Chinese‑developed epothilone; validates global development capability; success would open ex‑China markets and support premium valuation.
- For Chinese Biotech: Demonstrates capacity to execute US pivotal trials; regulatory pathway clarity for repurposing China‑approved drugs; potential template for other epothilone derivatives (e.g., utidelone’s success story).
- For Patients: New therapeutic option for HER2‑negative BCBM, a population with limited targeted therapies; lower cost may improve access in both developed and emerging markets.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Utedelone’s clinical development timeline, market penetration, and regulatory approval. Actual results may differ due to clinical risks, regulatory feedback, or competitive responses.-Fineline Info & Tech
